top of page

Publications

Peer-reviewed journal articles for which I provided medical writing support.

Garlapati C, Joshi S, Bhattarai S, et al. PLK1 and AURKB phosphorylate survivin differentially to affect proliferation in racially distinct triple-negative breast cancer. Cell Death Dis. 2023;14(1):12. doi:10.1038/s41419-022-05539-5

Kaur J, Chandrashekar DS, Varga Z, et al. Whole-exome sequencing reveals high mutational concordance between primary and matched recurrent triple-negative breast cancersGenes. 2023; 14(9):1690. doi:10.3390/genes14091690

Skowronska-Krawczyk D. Hallmarks of aging: causes and consequencesAgingBio, 2023;1:1–3. doi:10.59368/agingbio.20230011

Bhattarai S, Saini G, Li H, et al. Predicting neoadjuvant treatment response in triple-negative breast cancer using machine learning. Preprint. bioRxiv. 2023;2023.04.17.536459. doi:10.1101/2023.04.17.536459

Fisher TB, Saini G, Ts R, et al. Digital image analysis and machine learning-assisted prediction of neoadjuvant chemotherapy response in triple-negative breast cancer. Preprint. Research Square; 2023. doi:10.21203/rs.3.rs-3243195/v1

Xu Q, Kaur J, Wylie D, et al. A case series exploration of multi-regional expression heterogeneity in triple-negative breast cancer patients. Int J Mol Sci. 2022;23(21):13322. doi:10.3390/ijms232113322
Luningham JM, Seth G, Saini G, et al. Association of race and area deprivation with breast cancer survival among Black and White women in the state of Georgia. JAMA Netw Open. 2022;5(10):e2238183. doi:10.1001/jamanetworkopen.2022.38183
Lu S, Cheng Y, Huang D, et al. Efficacy and safety of selpercatinib in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer: a phase II clinical trial (LIBRETTO-321). Ther Adv Med Oncol. 2022;14:17588359221105020. 
doi:10.1177/17588359221105020
Kaur J, Chandrashekar DS, Varga Z, et al. Distinct gene expression profiles of matched primary and metastatic triple-negative breast cancers. Cancers (Basel). 2022;14(10):2447. doi:10.3390/cancers14102447
Sugita BM, Rodriguez Y, Fonseca AS, et al. MiR-150-5p overexpression in triple-negative breast cancer contributes to the in vitro aggressiveness of this breast cancer subtype. Cancers (Basel). 2022;14(9):2156. doi:10.3390/cancers14092156
Mei WJ, Mi M, Qian J, Xiao N, Yuan Y, Ding PR. Clinicopathological characteristics of high microsatellite instability/mismatch repair-deficient colorectal cancer: A narrative review. Front Immunol. 2022;13:1019582. doi:10.3389/fimmu.2022.1019582
Mao L, Qi Z, Zhang L, Guo J, Si L. Immunotherapy in acral and mucosal melanoma: Current status and future directions. Front Immunol. 2021;12:680407.  doi:10.3389/fimmu.2021.680407
Adhyapak P, Dong W, Dasgupta S, Dutta A, Duan M, Kapoor S. Lipid clustering in mycobacterial cell envelope layers governs spatially resolved solvation dynamics. Chem Asian J. 2022;17(11):e202200146. doi:10.1002/asia.202200146
Xiong A, Wang J, Zhou C. Immunotherapy in the first-line treatment of NSCLC: Current status and future directions in China. Front Oncol. 2021;11:757993.  doi:10.3389/fonc.2021.757993
Henderson F, Johnston HR, Badrock AP, et al. Enhanced fatty acid scavenging and glycerophospholipid metabolism accompany melanocyte neoplasia progression in zebrafish. Cancer Res. 2019;79(9):2136-2151. doi:10.1158/0008-5472.CAN-18-2409
Grees M, Sharbi-Yunger A, Evangelou C, et al. Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models. Oncoimmunology. 2018;7(7):e1445457. doi:10.1080/2162402X.2018.1445457
Karapetsas A, Tokamani M, Evangelou C, Sandaltzopoulos R. The homeodomain transcription factor MEIS1 triggers chemokine expression and is involved in CD8+ T-lymphocyte infiltration in early stage ovarian cancer. Mol Carcinog. 2018;57(9):1251-1263. doi:10.1002/mc.22840

Conference coverage

For a more comprehensive list, please visit my MuckRack profile.

Feature articles

For a more comprehensive list, please visit my MuckRack profile.

Pathology News

bottom of page